Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1373-1381

  Bernardino, J I ^a   Pulido, F ^b   Martinez, E ^c   Arrizabalaga, J ^d   Domingo, P ^c   Portilla, J ^e   Ocampo, A ^f   Munoz J ^g   Torres, R ^h   Arribas, J R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^g HOSPITAL DE BASURTO   (Spain)

^h HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

HIV; Lipoatrophy; Lopinavir ritonavir monotherapy; NRTI sparing regimen; Thymidine nucleoside analogues

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAT MASS; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INTENTION TO TREAT ANALYSIS; LIPOATROPHY; LIPOHYPERTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUDDEN DEATH; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

HIV; LIPOATROPHY; LOPINAVIR/RITONAVIR MONOTHERAPY; NRTI-SPARING REGIMEN; THYMIDINE NUCLEOSIDE ANALOGUES;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATROPHY; BODY COMPOSITION; CHEMISTRY, PHARMACEUTICAL; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INTENTION TO TREAT ANALYSIS; LAMIVUDINE; LIPIDS; LIPODYSTROPHY; LOPINAVIR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT FAILURE;

EID: 84884619356     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks540     Document Type: Article

References (31)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
2. Carr A, Emery S, Law M et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726-35.
3. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006; 42: 562-71.
4. Bacchetti P, Gripshover B, Grunfeld C et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40: 121-31.
5. Duran S, Saves M, Spire B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001; 15: 2441-4.
6. Blanch J, Rousaud A, Martinez E et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004; 38: 1464-70.
7. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
8. Lichtenstein KA, Ward DJ, Moorman AC et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389-98.
9. Nguyen A, Calmy A, Schiffer V et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008; 9: 142-50.
10. Han SH, Zhou J, Saghayam S et al. Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocr J 2011; 58: 475-84.
11. Mallon PW, Miller J, Cooper DA et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-9.
12. Dube MP, Parker RA, Tebas P et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19: 1807-18.
13. Mallal SA, John M, Moore CB et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-16.
14. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
15. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, Lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
16. Podzamczer D, Ferrer E, Sanchez P et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44: 139-47.
17. Haubrich RH, Riddler SA, DiRienzo AG et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-188.
18. McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-70.
19. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-36.
20. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
21. Fisher M, Moyle GJ, Shahmanesh M et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009; 51: 562-8.
22. Tebas P, Zhang J, Yarasheski K et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 2007; 45: 193-200.
23. Tebas P, Zhang J, Hafner R et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009; 63: 998-1005.
24. Valantin MA, Lanoy E, Bentata M et al. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med 2008; 9: 625-35.
25. Cameron DW, da Silva BA, Arribas JR et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198: 234-40.
26. Bonnet E, Delpierre C, Sommet A et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom 2005; 8: 287-92.
27. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the Drug Resistance Mutations in HIV-1: December 2008. Top HIV Med 2008; 16: 138-145.
28. Martin A, Amin J, Emery S et al. Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One 2011; 6: e26885.
29. Kolta S, Flandre P, Van PN et al. Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial. Curr HIV Res 2011; 9: 31-9.
30. Valantin M, Kolta S, Flandre P et al. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 Substudy. HIV Med 2012; 13: 505-15.
31. Meynard JL, Bouteloup V, Landman R et al. Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother 2010; 65: 2436-44.